DIRECTED BIOTICS Trademark

Trademark Overview


On Saturday, January 11, 2020, a trademark application was filed for DIRECTED BIOTICS with the United States Patent and Trademark Office. The USPTO has given the DIRECTED BIOTICS trademark a serial number of 88755639. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Tuesday, October 20, 2020. This trademark is owned by PEBBLE LABS USA INC.. The DIRECTED BIOTICS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Medical research and development in the field of synthetic biology, molecular biology, genetic engineering and bioinformatics; Design and development of biological RNA-based therapeutic agents for the prevention and treatment of infectious diseases in plants and animals for use in pharmaceuticals, biotechnology, and medical and diagnostic applications; Research and development of biopharmaceutical compounds; Research and development of biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Research and development of biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit the expression of target pathogen genes in plants and animals; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit vector-borne diseases; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit aquaculture-related diseases; Research and deve...
directed biotics

General Information


Serial Number88755639
Word MarkDIRECTED BIOTICS
Filing DateSaturday, January 11, 2020
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateTuesday, October 20, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesMedical research and development in the field of synthetic biology, molecular biology, genetic engineering and bioinformatics; Design and development of biological RNA-based therapeutic agents for the prevention and treatment of infectious diseases in plants and animals for use in pharmaceuticals, biotechnology, and medical and diagnostic applications; Research and development of biopharmaceutical compounds; Research and development of biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Research and development of biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit the expression of target pathogen genes in plants and animals; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit vector-borne diseases; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit aquaculture-related diseases; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit mosquito populations; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit bacterial quorum-sensing; Research and development of genetically engineered organisms; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit the expression of target genes; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit the expression of target pathogen genes in plants and animals; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit vector-borne diseases; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit aquaculture-related diseases; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit mosquito populations; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit bacterial quorum-sensing; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce that produce eukaryotic-like mRNA; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce that produce commercial compounds; Research and development services, namely, RNA-based systems for yield management in plants; ; Research and development services, namely, plant transformation, plant transformation, bacterial-mediated transient eukaryotic cell transformation; Bioinformatic services, namely, rational design of novel pharmaceuticals, therapeutics and biologics

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, January 16, 2020
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePEBBLE LABS USA INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSANTA FE, NM 87501

Trademark Events


Event DateEvent Description
Tuesday, October 20, 2020ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Tuesday, October 20, 2020ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Wednesday, April 8, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, April 8, 2020NON-FINAL ACTION E-MAILED
Wednesday, April 8, 2020NON-FINAL ACTION WRITTEN
Monday, March 30, 2020ASSIGNED TO EXAMINER
Thursday, January 16, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Wednesday, January 15, 2020NEW APPLICATION ENTERED IN TRAM